Press Releases

Appointment of Piper Jaffray as Nominated Advisor & Broker

1 December 2009

Porton Down, UK, 1 December 2009 - GW Pharmaceuticals plc (AIM: GWP) is pleased to announce the appointment, with immediate effect, of Piper Jaffray Ltd as Nominated Advisor and broker to the Company.... more

Sativex® Phase II/III Cancer Pain Study Completes Patient Recruitment

25 November 2009

Porton Down, UK, 25 November 2009: GW Pharmaceuticals plc (GWP:AIM) announces that it has completed recruitment into its Sativex® Phase II/III cancer pain trial. This study is being carried out in co... more

Preliminary Results for the Year Ended 30 September 2009

25 November 2009

Porton Down, UK, 25 November 2009: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its preliminary results for ... more

Positive results from clinical study of Sativex in cancer pain published in peer review journal

23 November 2009

Porton Down, UK, 23 November 2009: GW Pharmaceuticals plc (GWP:AIM) announces that the results of a clinical study of Sativex® in the treatment of cancer pain have been published in the highly-regarde... more

Home Office licenses research into medical uses of cannabis

14 September 2009

The Home Office has issued a licence for a British pharmaceuticals company to investigate the uses of cannabis as a medicine. ... more

GW Pharmaceuticals to present at Rodman and Renshaw Annual Global Investment Conference

10 September 2009

GW Pharmaceuticals plc (AIM: GWP) announces that its Managing Director, Justin Gover, will be presenting at the Rodman and Renshaw Annual Global Investment Conference in New York on Thursday, Septembe... more

Prominent US Healthcare Fund Subscribes for Significant Equity Stake in GW

6 August 2009

GW Pharmaceuticals plc (GWP:AIM), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex, today announces that it has signed an agreement with funds controlled by Gr... more

GW Receives Commercial Manufacturing Licence for Sativex

16 July 2009

GW Pharmaceuticals plc (GWP:AIM) today announces that it has passed a Good Manufacturing Practice (GMP) inspection by the UK regulatory authority of its new in-house commercial manufacturing facility ... more

GW Expands Cannabinoid Research in the Field of Diabetes and Metabolic Disease

16 June 2009

GW Pharmaceuticals plc (GWP:AIM) today announces that it has entered into an exclusive strategic alliance with Professor Mike Cawthorne and the Clore Laboratory, University of Buckingham, focusing on ... more

Interim Results For The Six Months Ended 31 March 2009

20 May 2009

GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex, announces its interim results for the six months ended 31 March 2009.... more

GW Files Sativex Regulatory Submission

20 May 2009

GW Pharmaceuticals plc (GWP:AIM) today announces that it has filed a regulatory submission for Sativex for the treatment of spasticity due to Multiple Sclerosis. This submission follows the recent ann... more

GW Announces £8m Milestone Payment from Almirall

1 April 2009

GW Pharmaceuticals plc (GWP:AIM) today announces that it has received confirmation from its licensing partner, Laboratorios Almirall S.A., that it will pay to GW a milestone payment of GBP 8 million. ... more

GW Phase III Spasticity Results - Analyst Presentation

11 March 2009

GW Phase III Spasticity Results - Analyst Presentation GW Pharmaceuticals plc hosted todays Phase III Spasticity Results Analyst Presentation on Wednesday 11th March 2009 at 2:30pm.... more

Positive Outcome of Sativex Phase III MS Study

11 March 2009

GW Pharmaceuticals plc (GWP:AIM) today announces positive preliminary results from a pivotal Phase III double-blind randomised placebo-controlled study of Sativex in patients with spasticity due to M... more

Positive Results in Randomized Withdrawal Sativex® Study Confirm Long Term Efficacy in MS Spasticity

24 February 2009

GW Pharmaceuticals plc (GWP:AIM) announces positive results from a placebo-controlled randomized withdrawal study of Sativex® in patients with spasticity due to Multiple Sclerosis (MS). This study was... more